Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 1140361-24-042795 0001790787 XXXXXXXX LIVE 6 Common stock, $0.001 par value per share 08/11/2026 0001625297 45579U109 Indivior Pharmaceuticals, Inc. 10710 Midlothian Turnpike Suite 125 North Chesterfield VA 23235 Martin Boskovich (213) 830-6759 333 South Grand Avenue 28th Floor Los Angeles CA 90071 Y Oaktree Value Opportunities Fund, L.P. WC E9 0.00 385037.00 0.00 385037.00 385037.00 0.32 PN The reported securities represent 385,037 shares of common stock ("Common Stock") issuable upon conversion of Notes (as defined below). The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on August 3, 2026 (the "Form 10-Q"), and as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. Y Oaktree London Liquid Value Opportunities Fund (VOF), L.P. WC DE 0.00 180169.00 0.00 180169.00 180169.00 0.15 PN The reported securities represent 180,169 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. Y Oaktree Phoenix Investment Fund, L.P. WC E9 0.00 51271.00 0.00 51271.00 51271.00 0.04 PN The reported securities represent 51,271 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. Y Oaktree Capital Management, L.P. WC Y DE 0.00 292576.00 0.00 292576.00 292576.00 0.25 PN The reported securities represent 292,576 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. Y Oaktree Fund GP I, L.P. WC DE 0.00 616477.00 0.00 616477.00 616477.00 0.52 PN The reported securities represent 616,477 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. 0001790787 N Oaktree Capital Holdings, LLC WC DE 0.00 909053.00 0.00 909053.00 909053.00 0.76 OO The reported securities represent 909,053 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. Common stock, $0.001 par value per share Indivior Pharmaceuticals, Inc. 10710 Midlothian Turnpike Suite 125 North Chesterfield VA 23235 This Amendment No. 6 (this "Amendment No. 6") amends and supplements the Schedule 13D, originally filed on October 2, 2024, as amended by Amendment No. 1 filed on November 7, 2024, as amended by Amendment No. 2 filed on December 18, 2024, as amended by Amendment No. 3 filed on March 4, 2025, as amended by Amendment No. 4 filed on November 13, 2025, and as amended by Amendment No. 5 filed on December 30, 2025. Except as set forth herein, the Schedule 13D remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D. Item 3 of the Schedule 13D is hereby amended and supplemented to insert the following at the end thereof: On various dates since the filing of Amendment No. 5, the Reporting Persons and certain of their affiliated funds and accounts engaged in open market purchases and sales of the Issuer's 0.625% Convertible Senior Notes due 2031 (the "Notes"), which are convertible into shares of Common Stock at an approximate conversion rate of $41.66 per share. The purchases of the Notes were pursuant to open market transactions, funded with working capital. As of the filing of this Statement, the Reporting Persons beneficially own an aggregate principal amount of $37.872 million of Notes convertible into 909,053 shares of Common Stock. Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended and restated as follows and as set forth in subsection (b), (c) and (e) hereto: The information set forth in rows (11) and (13) of each cover page of this Amendment No. 6 is incorporated by reference into this Item 5(a). The Reporting Persons beneficially own an aggregate of 909,053 shares of Common Stock issuable upon conversion of $37.872 million of Notes, representing 0.76% of the Common Stock outstanding as of the date hereof. All such ownership percentages of the securities reported herein are calculated assuming 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed by the Issuer in its Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. In this regard, OVO Fund is the direct holder of 385,037 shares of Common Stock issuable upon conversion of Notes. VOF Fund is the direct holder of 180,169 shares of Common Stock issuable upon conversion of Notes. OPI Fund is the direct holder of 51,271 shares of Common Stock issuable upon conversion of Notes. OC Management is the investment manager to Boston Patriot Arlington St LLC, an SMA account which directly holds 103,622 shares of Common Stock issuable upon conversion of Notes. OC Management is also the investment manager of, and has included in its beneficial ownership securities held by, certain affiliated funds and accounts of the Reporting Persons that collectively hold 188,954 shares of Common Stock issuable upon conversion of Notes. Oaktree GP I is the indirect general partner of OVO Fund, VOF, and OPI Fund, and as such may be deemed to beneficially own an aggregate of 616,477 shares of Common Stock issuable upon conversion of Notes. OC Holdings is the indirect general partner of OVO Fund, VOF, OPI Fund, and Oaktree GP I, and is the sole managing member of the general partner of OC Management, and as such may be deemed to beneficially own an aggregate of 909,053 shares of Common Stock issuable upon conversion of Notes. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act or for any other purpose. The information set forth in rows (7) through (10) of each cover page of this Amendment No. 6 and the information set forth in Item 5(a) hereof is incorporated by reference into this Item 5(b). Within the last 60 days of the filing of this Amendment No. 6, the Reporting Persons have disposed of shares of Common Stock in open market transactions (collectively, the "Common Stock Transactions") as follows: Date Purchase/Sale Amount of Shares Price 26-Jun Sale 231,398 42.1308 26-Jun Sale 118,602 41.7051 16-Jul Sale 14,900 40.614 16-Jul Sale 25,100 40.6395 5-Aug Sale 432,613 38.8552 6-Aug Sale 428,711 39.2151 10-Aug Sale 235,364 38.6389 10-Aug Sale 143,935 38.5563 11-Aug Sale 303,621 38.7858 12-Aug Sale 4,542,968 37.75 Within the last 60 days of the filing of this Amendment No. 6, the Reporting Persons and certain of their affiliated funds and accounts have acquired and disposed of Notes in open market transactions as follows (collectively, the "Notes Transactions" and, together with the Common Stock Transactions, the "Transactions"): Date Purchase/Sale Principal Amount Price 23-Jun Sale $91,000 118.104 25-Jun Sale $70,000 120.327 9-Jul Purchase $500,000 121.285 4-Aug Sale $1,750,000 111.904 5-Aug Sale $2,000,000 116.201 6-Aug Sale $2,000,000 116.278 12-Aug Sale $111,000 114.168 As a result of the Transactions on or prior to August 10, 2026, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on such date. Additional sales on August 11, 2026 resulted in a material shift in ownership requiring the filing of this Amendment No. 6, which serves as an exit filing by the Reporting Persons. Exhibit 24.1 Joint Filing Agreement, dated as of August 13, 2026, by and among the Reporting Persons Oaktree Value Opportunities Fund, L.P. /s/ Henry Orren Henry Orren / Managing Director 08/13/2026 Oaktree London Liquid Value Opportunities Fund (VOF), L.P. /s/ Henry Orren Henry Orren / Managing Director 08/13/2026 Oaktree Phoenix Investment Fund, L.P. /s/ Henry Orren Henry Orren / Managing Director 08/13/2026 Oaktree Capital Management, L.P. /s/ Henry Orren Henry Orren / Managing Director 08/13/2026 Oaktree Fund GP I, L.P. /s/ Henry Orren Henry Orren / Managing Director 08/13/2026 Oaktree Capital Holdings, LLC /s/ Henry Orren Henry Orren / Managing Director 08/13/2026